Capricor Therapeutics CAPR Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Capricor Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Capricor Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Capricor Therapeutics's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Capricor Therapeutics's return on equity?
- Capricor Therapeutics (CAPR) reported return on equity of -56.4% in Q1 2026.
- How has Capricor Therapeutics's return on equity changed year-over-year?
- Capricor Therapeutics's return on equity increased by 25.2% year-over-year, from -75.4% to -56.4%.
- What is the long-term trend for Capricor Therapeutics's return on equity?
- Over 5 years (2020 to 2025), Capricor Therapeutics's return on equity has grown at a -9.8% compound annual growth rate (CAGR), from -78% to -46.6%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.